About Adjuvance Technologies
Adjuvance Technologies is a company based in New York (United States) founded in 2009.. Adjuvance Technologies has raised $13.37 million across 4 funding rounds from investors including NIH, HHS and Morningside. The company has 20 employees as of December 31, 2022. Adjuvance Technologies operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter New York, United States
- Employees 20 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adjuvance Technologies Inc.
-
Annual Revenue
$00as on Nov 14, 2016
-
Net Profit
-
EBITDA
-
Total Equity Funding
$13.37 M (USD)
in 4 rounds
-
Latest Funding Round
$1.47 M (USD), Grant
May 19, 2020
-
Investors
NIH
& 2 more
-
Employee Count
20
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Adjuvance Technologies
Adjuvance Technologies has successfully raised a total of $13.37M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $1.47 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $1.5M
-
First Round
First Round
(15 Jun 2014)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Grant - Adjuvance Technologies | Valuation |
investors |
|
| Nov, 2019 | Amount | Series A - Adjuvance Technologies | Valuation |
investors |
|
| Nov, 2016 | Amount | Series A - Adjuvance Technologies | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adjuvance Technologies
Adjuvance Technologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Morningside. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adjuvance Technologies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Adjuvance Technologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adjuvance Technologies Comparisons
Competitors of Adjuvance Technologies
Adjuvance Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adjuvance Technologies
Frequently Asked Questions about Adjuvance Technologies
When was Adjuvance Technologies founded?
Adjuvance Technologies was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Where is Adjuvance Technologies located?
Adjuvance Technologies is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Adjuvance Technologies a funded company?
Adjuvance Technologies is a funded company, having raised a total of $13.37M across 4 funding rounds to date. The company's 1st funding round was a Series A of $2.72M, raised on Jun 15, 2014.
How many employees does Adjuvance Technologies have?
As of Dec 31, 2022, the latest employee count at Adjuvance Technologies is 20.
What does Adjuvance Technologies do?
Adjuvance Technologies was founded in 2009 and is headquartered in New York, United States. Focus is placed on the biotechnology sector, where adjuvant molecules for vaccines are developed and produced. Synthetic production methods for these adjuvants are commercialized, while a range of novel adjuvants targeting cancer and infectious diseases is created through proprietary technology. Operations center on advancing vaccine formulations in this field.
Who are the top competitors of Adjuvance Technologies?
Adjuvance Technologies's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Who are Adjuvance Technologies's investors?
Adjuvance Technologies has 3 investors. Key investors include NIH, HHS, and Morningside.